Metabolic changes associated with antiretroviral therapy in HIV-positive patients;Alterações metabólicas associadas à terapia anti-retroviral em pacientes HIV-positivos

Revista de Saude Publica

Volumn 43, Issue 2, 2009, Pages 283-290

  de Matos Almeida, Sabrina Esteves ^a,b   Borges, Michele ^a,c   Fiegenbaum, Marilu ^a,d   Nunes, Cynara Carvalho ^e   Rosa Rossetti, Maria Lucia ^a,c  

^a Fundacao Estadual de Producao e Pesquisa em Saude   (Brazil)

^b UNIVERSIDADE FEEVALE   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^d Hospital Psiquiátrico São Pedro   (Brazil)

^e Prefeitura de Porto Alegre   (Brazil)

Author keywords

Anti HIV agents, adverse effects; Cholesterol, blood, epidemiologic studies; Comorbidity; Hepatitis C; HIV infections, prevention control; Lipid metabolism

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHOLESTEROL; GLUCOSE; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DYSLIPIDEMIA; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; GLUCOSE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; TRIGLYCERIDES;

EID: 69249208730     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0034-89102009005000005     Document Type: Article

References (21)

1. Aceti A, Pasquazzi C, Zechini B, De Bac C, Liverhaart Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr. 2002;29(1):41-8.
2. Asztalos BF, Schaefer EJ, Horvath KV, Cox CE, Skinner S, Gerrior J, et al. Protease inhibitor-based Haart, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis. 2006;184(1):72-7. DOI: 10.1016/j.atherosclerosis.2005.04.013.
3. Braitstein P, Justice A, Bangsberg DR, Yip B, Alfonso V, Schechter MT, et al. Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV Cohort. AIDS. 2006;20(3):323-31. DOI: 10.1097/01.aids.0000198091.70325.f4
4. Bucher HC, Kofler A, Nuesch R, Young J, Battegay M, Opravil M. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS. 2003;17(17):2451-9. DOI: 10.1097/00002030-200311210-00007
5. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53(Supl 1):10-4. DOI: 10.1093/jac/dkh013
6. Collazos J, Mayo J, Ibarra S, Cazallas J. Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection. AIDS. 2003;17(6): 9279. DOI: 10.1097/00002030-200304110-00023
7. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA. 1997;277(2):145-53. DOI: 10.1001/jama.277.2.145
8. De Larrañaga GF, Wingeyer SDAP, Puga LM, Alonso BS, Benetucci JA. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antriretroviral treatment. Eur J Clin Microbiol Infect Dis. 2006;25(2):98-103.
9. Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27(3):245-50.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001;285(19):2486-96. DOI: 10.1001/jama.285.19.2486
11. Friis-Moller N. Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993-2003. DOI: 10.1056/NEJMoa030218
12. Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol. 2005;95(5):586-91. DOI: 10.1016/j.amjcard.2004.11.004
13. Leitner JM, Pernerstorfer-Schoen H, Weiss A, Schindler K, Rieger A, Jilma B. Age and sex modulate metabolic and cardiovascular risk markers of patients after 1 year of highly active antiretroviral therapy (HAART). Atherosclerosis. 2006; 187(1):177-85. DOI: 10.1016/j.atherosclerosis.2005.09.001
14. Melvin DC, Lee JK, Belsey E, Arnold J, Murphy RL. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS. 2000; 14(Supl 4):463-5. DOI: 10.1097/00002030-200003100-00023
15. Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother. 2005;55(5):800-4. DOI: 10.1093/jac/dki063
16. Murphy RL. Defining the toxicity profile of nevirapine and other antiretroviral drugs. J Acquir Immune Defic Syndr. 2003;34(Supl 1):S15-20. DOI: 10.1097/00126334-200309011-00004
17. Patroni A, Patroni A, Torti C, Tomasoni L, Roldan EQ, Bertelli D, et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clinical Trials. 2002;3(6):451-61. DOI: 10.1310/W024-QC4T-NXU0-TKYT
18. Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr. 2005;39(Supl 2):199-202.
19. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14(1):51-57. DOI: 10.1097/00002030-200001070-00006
20. Sociedade Brasileira de Hipertensão. Sociedade Brasileira de Cardiologia. Sociedade Brasileira de Nefrologia. IV Consenso Brasileiro de Hipertensão Arterial. São Paulo; 2002.
21. Sociedade Brasileira de Diabetes. Consenso Brasileiro sobre Diabetes 2002. Diagnóstico e classificação do diabetes melito e tratamento do diabetes melito do tipo 2. Rio de Janeiro: Diagraphic Editora; 2003.